Progress and considerations in the research of malnutrition in patients with cirrhosis

Progress and considerations in the research of malnutrition in patients with cirrhosis

Malnutrition, a subacute or chronic nutritional condition, arises from insufficient (or excessive) food intake and/or inflammation, leading to compromised body composition and reduced bodily functions, adversely affecting clinical outcomes and prognosis. Given the liver's central role in metabolizing glucose, proteins, and fats, patients with ongoing liver damage, especially cirrhosis, commonly suffer from malnutrition. Studies indicate that 40% to 90% of hospitalized patients with liver disease experience malnutrition. It is an independent predictor of mortality in cirrhosis patients and is closely linked to complications like ascites, hepatic encephalopathy, infections, and recent findings also suggest connections with reduced quality of life, sleep disorders, micronutrient deficiencies, and frailty.
Dr. Massimo Federico: 10-Year Follow-up Results of Early FDG-PET Adaptive Treatment for Limited-Stage HL

Dr. Massimo Federico: 10-Year Follow-up Results of Early FDG-PET Adaptive Treatment for Limited-Stage HL

At the International Malignant Lymphoma Conference (ICML 2023), Dr. Massimo Federico from University of Modena and Reggio Emilia, presented a captivating report on 10-Year Follow-up Analysis of the EORTC/LYSA/FIL H10 Randomized Intergroup Trial during the "Focus on Hodgkin Lymphoma" session. Oncology Frontier specially invited Dr. Federico for an in-depth interview on this topic.
The clinical insights gained from T-cell receptor sequencing in revealing the immune characteristics of liver cancer staging

The clinical insights gained from T-cell receptor sequencing in revealing the immune characteristics of liver cancer staging

T lymphocytes play a crucial role in human adaptive immunity by recognizing antigens major histocompatibility complex (MHC) molecules through specific T-cell receptors (TCRs) on their surface. 95% of T cells have TCRs composed of α and β peptide chains connected by disulfide bonds, forming an α/β heterodimer. Each chain consists of constant and variable domains. TCR diversity arises from the rearrangement of the variable (V), diversity (D), and joining (J) gene segments of the peptide chains, along with random nucleotide additions or deletions.
APASL 2023 | Prof. George Lau: Seeking the “Cure” for Liver Disease – A Hepatologist’s Thirty-Year Journey of Exploration

APASL 2023 | Prof. George Lau: Seeking the “Cure” for Liver Disease – A Hepatologist’s Thirty-Year Journey of Exploration

The 32nd annual meeting of the Asia-Pacific Association for the Study of the Liver (APASL) was held at the Taipei International Convention Center in Taiwan, China, from February 15 to 19, 2023. During the conference, the APASL Executive Committee awarded four prestigious honors, including the third APASL Highest Honor Award, the Okuda-Omata Outstanding Achievement Award, to Professor George Lau. Professor Lau, Chairman of the Universal Benevolence Medical Group in Hong Kong, China, and Co-Director of the Liver Disease and Transplant Center at the Fifth Medical Center of the PLA General Hospital in Beijing, in collaboration with the Universal Benevolence Medical Group, was recognized for his distinguished achievements. In his acceptance speech, Professor Lau delivered an inspiring message, encouraging his peers in hepatology to continue their relentless pursuit of curing liver diseases. We extend our heartfelt congratulations to Professor Lau and are pleased to share a translated version of his speech for our readers' encouragement and inspiration.
ASH 2023丨Professor Lin Tongyu: Decoding ASH Conference Insights on Lymphoma Treatment, Potential Revealed in r/r-PTCL with EZH1/2 Inhibitor HH2853

ASH 2023丨Professor Lin Tongyu: Decoding ASH Conference Insights on Lymphoma Treatment, Potential Revealed in r/r-PTCL with EZH1/2 Inhibitor HH2853

From December 9 to 12, the highly anticipated 65th American Society of Hematology (ASH) Annual Meeting took place in San Diego, USA. Focused on the annual pinnacle in the field of hematologic malignancies, the front-line reporting team of "Oncology Insights" delved into the forefront, witnessing the outstanding performance of "China's Good Voice" on the international stage. In the realm of aggressive lymphomas, advancements in targeted and cellular immunotherapy continue to dominate. To comprehensively grasp the lymphoma treatment developments at this ASH conference, "Oncology Insights" had the privilege of interviewing Professor Lin Tongyu from Sun Yat-sen University Cancer Hospital, who provided insightful analysis on the topic.
ASH Exclusive Interview | Professor Junmin Li: Addition of Homoharringtonine Improves Induction Therapy Efficacy in Low to Intermediate-Risk AML Patients with Chemotherapy Insensitivity

ASH Exclusive Interview | Professor Junmin Li: Addition of Homoharringtonine Improves Induction Therapy Efficacy in Low to Intermediate-Risk AML Patients with Chemotherapy Insensitivity

Acute myeloid leukemia (AML) is a highly heterogeneous group with varying sensitivities to chemotherapy. The "7+3" regimen has been the standard induction chemotherapy for AML for 50 years. In the era of precision medicine, optimizing induction therapy for AML is a crucial issue. At the recent 65th American Society of Hematology (ASH) Annual Meeting, Professor Junmin Li's team from the Hematology Department of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, presented the initial results of the RJ-AML2016 study. This multicenter, randomized, Phase III trial investigated the efficacy of adding Homoharringtonine (HHT) to optimize the idarubicin and cytarabine induction regimen based on Day 5 Peripheral Blast Clearance Rate (D5-PBCR) in newly diagnosed young AML patients. "Hematology Frontier" had the privilege of interviewing Professor Li on the study's key findings and the team's next research plans.
ASH Big Shot Interview | Professor Jie Jin : IL1RAP-TCE Antibody Effectively Eliminates Leukemia Stem Cells in AML

ASH Big Shot Interview | Professor Jie Jin : IL1RAP-TCE Antibody Effectively Eliminates Leukemia Stem Cells in AML

From December 9 to 12, 2023, the 65th American Society of Hematology (ASH) Annual Meeting was grandly held in San Diego, USA, in a hybrid format combining online and offline sessions. As one of the largest and most comprehensive international academic conferences in the field of hematology, experts and scholars from around the world gathered to explore the latest frontiers in hematologic diseases, new treatment methods and strategies, and disease management approaches. At this year's ASH Annual Meeting, Professor Jin Jie and her team from the First Affiliated Hospital of Zhejiang University School of Medicine presented an oral report titled "IL1RAP-Specific T Cell Engager (TCE) Antibody Effectively Clears Leukemia Stem Cells (LSC) in Acute Myeloid Leukemia (AML)." "Tumor Watch" had the privilege of interviewing Professor Jin Jie on-site to discuss the research and its related content.
ASH China Voice | Prof. Huang Huiqiang: Final Follow-up Report on the Combined Treatment of Relapsed/Refractory Extranodal NK/T-Cell Lymphoma with Pembrolizumab and Sintilimab (SCENT)

ASH China Voice | Prof. Huang Huiqiang: Final Follow-up Report on the Combined Treatment of Relapsed/Refractory Extranodal NK/T-Cell Lymphoma with Pembrolizumab and Sintilimab (SCENT)

From December 9 to December 12, 2023, the 65th American Society of Hematology Annual Meeting (ASH) took place in San Diego. Experts from around the world in the field of hematologic malignancies gathered, presenting a wealth of exciting content. During this conference, Professor Huang Huiqiang and his team from Sun Yat-sen University Cancer Center reported the long-term follow-up results of their phase Ib/II clinical study on the use of immune checkpoint inhibitor (PD-1) in combination with sintilimab for the treatment of relapsed/refractory extranodal NK/T-cell lymphoma. At the ASH conference, "Oncology Insight" had the privilege of inviting Prof. Huang Huiqiang to provide insights into this groundbreaking research.
ASH 2023 | Prof. Fengkui Zhang and Prof. Bing Han Team: KP104 Effectively Controls Intravascular and Extravascular Hemolysis in PNH Patients Without Complement Inhibitor Treatment

ASH 2023 | Prof. Fengkui Zhang and Prof. Bing Han Team: KP104 Effectively Controls Intravascular and Extravascular Hemolysis in PNH Patients Without Complement Inhibitor Treatment

Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare and life-threatening blood disorder. Due to the complexity of complement biology and various pathogenic pathways, there remains a significant unmet clinical need, urgently requiring next-generation drugs with superior efficacy and dosing convenience compared to current therapies. At the recently held 65th American Society of Hematology (ASH) Annual Meeting, Prof. Fengkui Zhang from the Hematology Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology) and Prof. Bing Han's team from Peking Union Medical College Hospital presented an oral report (Abstract: 572). The study explored the safety and effectiveness of the dual-function C5 antibody/H factor fusion protein KP104 in PNH patients who had not received complement inhibitor treatment. This research brings hope to address this challenging issue and has been selected as a highlight of "ASH 2024." The summarized details are presented below in this issue of "Hematology Insight."